Compare Abbott Laboratories (ABT) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $436.08 (market cap $1.98T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 11.9× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | TSM | |
|---|---|---|
Market Cap | $166.94B | $1.98T |
Sector | Health | Technology |
52-Week High | $136.62 | $477.57 |
52-Week Low | $82.57 | $227.33 |
Enterprise Value | $193.69B | $1.90T |
Dividend Yield | 2.63% | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
TSM trades at $432.57, down 0.37% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q1 2026 EPS of $3.49, beating expectations, and maintains robust profitability with a 46.5% net income margin. Revenue growth accelerated to $3.81 trillion in 2025, up from $2.89 trillion in 2024, driven by AI chip demand. Analyst consensus is strongly bullish with a $493.75 price target, and the stock is near its 52-week high.
Outlook remains positive given TSM's critical role in AI semiconductor manufacturing and consistent earnings beats, but risks include geopolitical tensions in Taiwan, valuation premiums, and competitive pressures from hyperscalers developing in-house chips. The stock's premium P/E of 39.27 requires sustained high growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
